$ELOX
Eloxx Pharmaceuticals, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020023543 Filed on May 08, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.220M $5.960M
YoY Change -12.42% 75.81%
% of Gross Profit
Research & Development $4.767M $6.019M
YoY Change -20.8% 36.98%
% of Gross Profit
Depreciation & Amortization $19.00K $30.00K
YoY Change -36.67% 42.86%
% of Gross Profit
Operating Expenses $13.77M $11.98M
YoY Change 14.95% 40.11%
Operating Profit -$13.77M -$11.98M
YoY Change 14.95% 40.11%
Interest Expense -$180.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$179.0K $60.00K
YoY Change -398.33% -239.53%
Pretax Income -$13.95M -$11.92M
YoY Change 17.03% 38.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$13.95M -$11.92M
YoY Change 17.03% 38.71%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$348.1K -$331.9K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.96M $53.50M
YoY Change -17.84% 192.53%
Cash & Equivalents $25.88M $44.58M
Short-Term Investments $18.08M $8.928M
Other Short-Term Assets $1.970M $1.960M
YoY Change 0.51% 250.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.93M $55.46M
YoY Change -17.19% 194.36%
LONG-TERM ASSETS
Property, Plant & Equipment $182.0K $1.340M
YoY Change -86.42% 326.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $110.0K $94.00K
YoY Change 17.02%
Total Long-Term Assets $1.114M $1.431M
YoY Change -22.15% 355.73%
TOTAL ASSETS
Total Short-Term Assets $45.93M $55.46M
Total Long-Term Assets $1.114M $1.431M
Total Assets $47.04M $56.89M
YoY Change -17.31% 197.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.389M $2.240M
YoY Change -37.99% 3.08%
Accrued Expenses $3.568M $4.597M
YoY Change -22.38% 32.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.772M $984.0K
YoY Change 384.96%
Total Short-Term Liabilities $11.08M $8.420M
YoY Change 31.64% 49.0%
LONG-TERM LIABILITIES
Long-Term Debt $9.385M $13.41M
YoY Change -30.01%
Other Long-Term Liabilities $320.0K $630.0K
YoY Change -49.21%
Total Long-Term Liabilities $9.385M $13.41M
YoY Change -30.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.08M $8.420M
Total Long-Term Liabilities $9.385M $13.41M
Total Liabilities $20.78M $22.46M
YoY Change -7.46% 297.52%
SHAREHOLDERS EQUITY
Retained Earnings -$151.0M -$98.06M
YoY Change 53.95% 106.22%
Common Stock $179.0M $133.4M
YoY Change 34.18% 118.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.26M $34.43M
YoY Change
Total Liabilities & Shareholders Equity $47.04M $56.89M
YoY Change -17.31% 197.0%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$13.95M -$11.92M
YoY Change 17.03% 38.71%
Depreciation, Depletion And Amortization $19.00K $30.00K
YoY Change -36.67% 42.86%
Cash From Operating Activities -$11.92M -$9.190M
YoY Change 29.75% 61.31%
INVESTING ACTIVITIES
Capital Expenditures $16.00K
YoY Change -71.93%
Acquisitions
YoY Change
Other Investing Activities $15.79M $0.00
YoY Change
Cash From Investing Activities $15.79M -$8.942M
YoY Change -276.57% 15587.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $455.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -483.0K 5.180M
YoY Change -109.32%
NET CHANGE
Cash From Operating Activities -11.92M -9.190M
Cash From Investing Activities 15.79M -8.942M
Cash From Financing Activities -483.0K 5.180M
Net Change In Cash 3.382M -8.942M
YoY Change -137.82% 55.4%
FREE CASH FLOW
Cash From Operating Activities -$11.92M -$9.190M
Capital Expenditures $16.00K
Free Cash Flow -$9.206M
YoY Change 59.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
33783000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
43000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1390000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
18082000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
43000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1927000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Assets Current
AssetsCurrent
45927000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
182000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
11977000
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
13257000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3568000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
425000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10502000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
402000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40316034
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40125454
CY2020Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
190580
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5224000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5958000
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1703000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174515000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150965000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
26257000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47041000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11917000
CY2020Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1819000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40186469
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40030763
CY2019Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
403000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
43000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11807000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
57709000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
315000
CY2020Q1 us-gaap Liabilities
Liabilities
20784000
CY2019Q4 us-gaap Liabilities
Liabilities
22734000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
201000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
822000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
924000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
110000
CY2020Q1 us-gaap Assets
Assets
47041000
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
155706
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
178573000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1389000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
65000
CY2020Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
4772000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4549000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
507000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
499000
CY2020Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
43000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11084000
CY2020Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9385000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
403000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137019000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
36213000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58947000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
CY2020Q1 us-gaap Payments For Proceeds From Longterm Investments
PaymentsForProceedsFromLongtermInvestments
-39000
CY2019Q1 us-gaap Payments For Proceeds From Longterm Investments
PaymentsForProceedsFromLongtermInvestments
3000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15789000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8942000
CY2019Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15000000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35910270
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
47000
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13899000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11916000
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
91000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
573000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
183000
CY2019Q1 elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-114000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6019000
CY2020Q1 elox Restructuring Charges Includes Stock Based Compensation
RestructuringChargesIncludesStockBasedCompensation
3994000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-13946000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40074275
CY2019Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
276000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
833000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
455000
CY2019Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1104000
CY2020Q1 elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
402000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-483000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3382000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44576000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
43000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
272000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
93000
CY2019Q1 elox Fair Value Of Warrants Issued In Connection With Long Term Debt
FairValueOfWarrantsIssuedInConnectionWithLongTermDebt
421000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2020Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-116000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3995000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
42911000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
421000
CY2019Q1 elox Restricted Stock Vested During Period Value
RestrictedStockVestedDuringPeriodValue
-121000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2658000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
34433000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
488000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
264000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
287000
CY2020Q1 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
822000
CY2019Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1560000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
714000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2200000
CY2020Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1326000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
507000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
664000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
137000
CY2020Q1 elox Accrued Interest On Debt
AccruedInterestOnDebt
77000
CY2019Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
94000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5000000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5000000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
417000
CY2020Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14167000
CY2020Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
910000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
217000
CY2020Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
21000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
26000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
446000
CY2020Q1 us-gaap Prepaid Insurance
PrepaidInsurance
258000
CY2020Q1 elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800
CY2020Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
43957000
CY2020Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q1 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
1068000
CY2019Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
448000
CY2020Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
580000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
699000
CY2020Q1 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-900000
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
40834
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
323894
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
323894
CY2020Q1 elox Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
323894
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2020Q1 elox Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice
4.32
CY2019Q4 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P3Y8M26D
CY2020Q1 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P3Y5M26D
CY2020Q1 elox Class Of Warrant Or Right Exercisable Expiration Period
ClassOfWarrantOrRightExercisableExpirationPeriod
P3Y5M26D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4737670
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1186810
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10636
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1022887
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4890957
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2344434
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.17
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.58
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.55
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.44
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.60
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M14D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M13D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3629073
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
438756
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
419318
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3995000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2658000
CY2020Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25875000
CY2020Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities Amortized Cost
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAmortizedCost
43892000
CY2020Q1 elox Cash And Cash Equivalent And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
-65000
CY2020Q1 elox Fair Value Assets Transfers Between Level2 And Level3 Description
FairValueAssetsTransfersBetweenLevel2AndLevel3Description
the Company did not have any transfers of financial assets between Level 2 and 3
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
245000
CY2019Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
288000
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14000
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10000
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2000
CY2019Q1 us-gaap Investment Income Net
InvestmentIncomeNet
3000
CY2020Q1 us-gaap Interest Expense Other
InterestExpenseOther
412000
CY2019Q1 us-gaap Interest Expense Other
InterestExpenseOther
221000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5592890
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4928446
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
13
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
4000000
CY2020Q1 elox Restructuring And Related Cost Stock Based Compensation Expense
RestructuringAndRelatedCostStockBasedCompensationExpense
2100000
CY2020Q1 elox Restructuring And Related Costs Severance Cost Payment Period
RestructuringAndRelatedCostsSeveranceCostPaymentPeriod
P1Y
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
1870000
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
544000
CY2020Q1 us-gaap Restructuring Reserve
RestructuringReserve
1326000

Files In Submission

Name View Source Status
0001564590-20-023543-index-headers.html Edgar Link pending
0001564590-20-023543-index.html Edgar Link pending
0001564590-20-023543.txt Edgar Link pending
0001564590-20-023543-xbrl.zip Edgar Link pending
elox-10q_20200331.htm Edgar Link pending
elox-20200331.xml Edgar Link completed
elox-20200331.xsd Edgar Link pending
elox-20200331_cal.xml Edgar Link unprocessable
elox-20200331_def.xml Edgar Link unprocessable
elox-20200331_lab.xml Edgar Link unprocessable
elox-20200331_pre.xml Edgar Link unprocessable
elox-ex311_7.htm Edgar Link pending
elox-ex312_8.htm Edgar Link pending
elox-ex321_6.htm Edgar Link pending
elox-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending